Sulzmaier FJ - Search Results

1

FAK Inhibition disrupts a β5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth.

Tancioni I, Uryu S, Sulzmaier FJ, Shah NR, Lawson C, Miller NL, Jean C, Chen XL, Ward KK, Schlaepfer DD. Tancioni I, et al. Among authors: sulzmaier fj. Mol Cancer Ther. 2014 Aug;13(8):2050-61. doi: 10.1158/1535-7163.MCT-13-1063. Epub 2014 Jun 4. Mol Cancer Ther. 2014. PMID: 24899686 Free PMC article.

2

Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.

Shah NR, Tancioni I, Ward KK, Lawson C, Chen XL, Jean C, Sulzmaier FJ, Uryu S, Miller NL, Connolly DC, Schlaepfer DD. Shah NR, et al. Among authors: sulzmaier fj. Gynecol Oncol. 2014 Jul;134(1):104-11. doi: 10.1016/j.ygyno.2014.04.044. Epub 2014 Apr 27. Gynecol Oncol. 2014. PMID: 24786638 Free PMC article.

3

FAK in cancer: mechanistic findings and clinical applications.

Sulzmaier FJ, Jean C, Schlaepfer DD. Sulzmaier FJ, et al. Nat Rev Cancer. 2014 Sep;14(9):598-610. doi: 10.1038/nrc3792. Epub 2014 Aug 7. Nat Rev Cancer. 2014. PMID: 25098269 Free PMC article. Review.

4

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy.

Diaz Osterman CJ, Ozmadenci D, Kleinschmidt EG, Taylor KN, Barrie AM, Jiang S, Bean LM, Sulzmaier FJ, Jean C, Tancioni I, Anderson K, Uryu S, Cordasco EA, Li J, Chen XL, Fu G, Ojalill M, Rappu P, Heino J, Mark AM, Xu G, Fisch KM, Kolev VN, Weaver DT, Pachter JA, Győrffy B, McHale MT, Connolly DC, Molinolo A, Stupack DG, Schlaepfer DD. Diaz Osterman CJ, et al. Among authors: sulzmaier fj. Elife. 2019 Sep 3;8:e47327. doi: 10.7554/eLife.47327. Elife. 2019. PMID: 31478830 Free PMC article.

5

Oxidized LDL induces FAK-dependent RSK signaling to drive NF-κB activation and VCAM-1 expression.

Yurdagul A Jr, Sulzmaier FJ, Chen XL, Pattillo CB, Schlaepfer DD, Orr AW. Yurdagul A Jr, et al. Among authors: sulzmaier fj. J Cell Sci. 2016 Apr 15;129(8):1580-91. doi: 10.1242/jcs.182097. Epub 2016 Feb 18. J Cell Sci. 2016. PMID: 26906414 Free PMC article.

6

PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.

Gawecka JE, Geerts D, Koster J, Caliva MJ, Sulzmaier FJ, Opoku-Ansah J, Wada RK, Bachmann AS, Ramos JW. Gawecka JE, et al. Among authors: sulzmaier fj. Int J Cancer. 2012 Oct 1;131(7):1556-68. doi: 10.1002/ijc.27415. Epub 2012 Jan 31. Int J Cancer. 2012. PMID: 22213050 Free PMC article.

7

RSK isoforms in cancer cell invasion and metastasis.

Sulzmaier FJ, Ramos JW. Sulzmaier FJ, et al. Cancer Res. 2013 Oct 15;73(20):6099-105. doi: 10.1158/0008-5472.CAN-13-1087. Epub 2013 Oct 4. Cancer Res. 2013. PMID: 24097826 Free PMC article. Review.

8

Phosphorylation is the switch that turns PEA-15 from tumor suppressor to tumor promoter.

Sulzmaier F, Opoku-Ansah J, Ramos JW. Sulzmaier F, et al. Small GTPases. 2012 Jul-Sep;3(3):173-7. doi: 10.4161/sgtp.20021. Epub 2012 Jun 14. Small GTPases. 2012. PMID: 22694972 Free PMC article.

9

PEA-15 potentiates H-Ras-mediated epithelial cell transformation through phospholipase D.

Sulzmaier FJ, Valmiki MK, Nelson DA, Caliva MJ, Geerts D, Matter ML, White EP, Ramos JW. Sulzmaier FJ, et al. Oncogene. 2012 Jul 26;31(30):3547-60. doi: 10.1038/onc.2011.514. Epub 2011 Nov 21. Oncogene. 2012. PMID: 22105357 Free PMC article.

10

The death effector domain protein PEA-15 negatively regulates T-cell receptor signaling.

Pastorino S, Renganathan H, Caliva MJ, Filbert EL, Opoku-Ansah J, Sulzmaier FJ, Gawecka JE, Werlen G, Shaw AS, Ramos JW. Pastorino S, et al. Among authors: sulzmaier fj. FASEB J. 2010 Aug;24(8):2818-28. doi: 10.1096/fj.09-144295. Epub 2010 Mar 30. FASEB J. 2010. PMID: 20354143 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

20 results

Search Page